Florcicaper (18F)
CAS 855927-17-2
MF C18H3318FO2, MW 299.4544
2-[(1S,2R)-2-(5-(18F)fluorotridecyl)cyclopropyl]acetic acid
| 2-((1S,2R)-2-(5-(FLUORO-18F)TRIDECYL)CYCLOPROPYL)ACETIC ACID |
| TRANS-9(RS)-18F-FLUORO-3,4(RS,RS)-METHYLENEHEPTADECANOIC ACID |
rac-{(1R,2S)-2-[(5RS)-5-(18F)fluorotridecyl]cyclopropyl}aceticacid
imaging agent, CARDIOPET, (18F FCPHA), FDG79C95XB
CardioPET is: An F-18 labeled, modified fatty acid that provides insight into regions with decreased blood flow or metabolic insufficiency in the myocardium.; CardioPET may be used to: Identify patients that will benefit from PCI or revascularization and guide intervention, Assess myocardial viability, Evaluate CAD in patients that cannot exercise.; Agent: Muscle State Imaging Agent, Type: Fatty Acid (Labeled with Fluorine 18), Condition: Coronary Artery Disease, Status: completed enrollment.;This imaging agent exploits the dietary needs of the heart as it relates to glucose and fatty acids. By introducing a radio-labeled analog to the natural fatty acids utilized as an energy source by the heart we can visualize the anatomic location and state of the muscle within the areas defined by the specific coronary artery blood flow distribution and detect problems in advance of symptoms that would lead to a stress test.
Cardiopet is under investigation in clinical trial NCT01826773 (Cardiopet as PET Imaging Agent to Assess Myocardial Perfusion and Fatty Acid Uptake in Known or Suspected CAD Subjects).
A Phase I Study in Healthy Volunteers to Evaluate the Safety of CardioPET™ in Detection of Coronary Artery Disease
CTID: NCT00413647
Phase: Phase 1
Status: Completed
Date: 2013-06-12
PATENTS
CA-2876139-A1 CN-104684546-A CN-114736112-A CN-115141087-A CN-115141087-B CN-115141125-A CN-115141125-B CN-115181013-A CN-115181013-B CN-115850224-A CN-115850224-B CN-115959978-A CN-115959978-B CN-116041169-A CN-116199658-A CN-116217356-A EP-2858630-A1 EP-4133284-A1 US-10533059-B2 US-11701429-B2 US-2015361110-A1 US-2017014528-A1 US-2020199249-A1 US-2020297854-A1 US-20230314449-A1 US-20230381092-A1 US-9409927-B2 WO-2013185032-A1 WO-2022082327-A1 WO-2023085674-A1 WO-2023236978-A1 WO-2023237092-A1
PAT
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2013185032&_cid=P11-MPJ5UV-89230-1
PAT
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022082327&_cid=P11-MPJ5WJ-90048-1
ADVT
ANAX LABORATORIES
WEBSITE https://www.anaxlab.com/
Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences
Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales
SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect
Phone : +91 897704 2010 / +91 9177075735, Email : info@anaxlab.com
#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma
AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
References
- Nanotherapeutics for drug targetingPublication Number: WO-2013185032-A1Priority Date: 2012-06-07
- Nanotherapeutics for drug targetingPublication Number: EP-2858630-A1Priority Date: 2012-06-07
- Super lewis acidic borate esters as 18F-labeled PET probesPublication Number: US-9409927-B2Priority Date: 2013-01-24Grant Date: 2016-08-09
- Super lewis acidic borate esters as 18f-labeled pet probesPublication Number: US-2015361110-A1Priority Date: 2013-01-24
- Nanotherapeutics for drug targetingPublication Number: CA-2876139-A1Priority Date: 2012-06-07
- Nanotherapeutics for drug targetingPublication Number: US-2020297854-A1Priority Date: 2012-06-07
- Nanotherapeutics for drug targetingPublication Number: CN-104684546-APriority Date: 2012-06-07
- Diagnosis of stage b2 dmvdPublication Number: US-2023314449-A1Priority Date: 2020-04-07
- Targeted drug delivery through affinity based linkersPublication Number: US-2017014528-A1Priority Date: 2014-03-12
- Targeted drug delivery through affinity based linkersPublication Number: US-2020199249-A1Priority Date: 2014-03-12
- Targeted drug delivery through affinity based linkersPublication Number: US-10533059-B2Priority Date: 2014-03-12Grant Date: 2020-01-14
- Targeted drug delivery through affinity based linkersPublication Number: US-11701429-B2Priority Date: 2014-03-12Grant Date: 2023-07-18
//////////florcicaper (18F), anax labs, imaging agent, CARDIOPET, (18F FCPHA), FDG79C95XB